News for OPKO Health, Inc. (0KCS.L)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Charles T. Todd, Jr. named CEO and Chair of the Board MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / Ludwig Enterprises, Inc. (the "Company"), has appointe

Camtek and NICE led the strong gains today but Elbit fell again.

Summary OPKO Health Inc (OPK), a multinational biopharmaceutical and diagnostics company, has announced that it will release its financial results for the first

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( OPK) plans to report operating and financial results for the three months ended March 31, 2025 a

PR NewswireCOCONUT GROVE, Fla., April 11, 2025 The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities for Futur

On April 4, 2025, OPKO Health Inc (OPK), a multinational biopharmaceutical and diagnostics company, announced that its Board of Directors has authorized an addi

MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( OPK) today announced that its Board of Directors has authorized an increase of $100 million to t

Hedge Fund Icon Ray Dalio Explains Tariffs In Simple Terms We Can All Understand (The Basis Point) Hedge Fund Boss Paul Marshall Bet Big On Elon Musk Before Trump’s Election (Desmog.

JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. ( ENTX), a leader in the development of oral peptides and proteins replacement therapies, today

**media[579895]**

On March 17, 2025, OPKO Health Inc (OPK) announced a collaboration and license agreement with Entera Bio Ltd. to develop the first oral dual agonist GLP-1/gluca

MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. ( OPK) and Entera Bio Ltd. ( ENTX), a leader in the development of oral peptides and

Investors are grappling with Trump-fueled stock market volatility in 2025.

PR NewswireBURLINGTON, N.C. and MIAMI, March 11, 2025 Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-qualit

OPKO Health Inc's diversified healthcare portfolio positions it for growth in multiple medical markets.Strategic partnerships and proprietary technologies bols

Diagnostic Segment Revenue: $103.1 million for Q4 2024, compared to $124.2 million for Q4 2023.Pharmaceutical Segment Revenue: $80.5 million for Q4 2024, compa

Feb 27, 2025 / 09:30PM GMTOperator Good day. And welcome to the OPKO Health fourth quarter 2024 Financial Results Conference Call. All participants will be in a

OPKO Health, Inc. (NASDAQ:OPK) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.